Diamyd Medical says retogatein delays insulin need by 5.6 years in diabetes prevention trial responder group

• Diamyd Medical published results from a randomized, placebo-controlled diabetes prevention Immune Tolerance Trial of retogatein.
• Data had been previously announced, then published in a scientific journal.
• Retogatein delayed the need for insulin in treatment responders, supporting a potential role in postponing insulin-dependent type 1 diabetes onset.
• Management highlighted a favorable safety profile, with a simple regimen requiring two injections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Diamyd Medical AB published the original content used to generate this news brief via Cision (Ref. ID: 202609290430BITN____UKPR__EN_20260929-BIT-6566-0) on September 29, 2026, and is solely responsible for the information contained therein.